Givosiran Sodium Patent Expiration
Givosiran Sodium is Used for treating acute hepatic porphyria. It was first introduced by Alnylam Pharmaceuticals Inc
Givosiran Sodium Patents
Given below is the list of patents protecting Givosiran Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Givlaari | US10119143 | Compositions and methods for inhibiting expression of the ALAS1 gene | Oct 03, 2034 | Alnylam Pharms Inc |
| Givlaari | US10125364 | Compositions and methods for inhibiting expression of the ALAS1 gene | Mar 15, 2033 | Alnylam Pharms Inc |
| Givlaari | US10131907 | Glycoconjugates of RNA interference agents | Aug 24, 2028 | Alnylam Pharms Inc |
| Givlaari | US10273477 | Therapeutic compositions |
Mar 08, 2024
(Expired) | Alnylam Pharms Inc |
| Givlaari | US11028392 | Compositions and methods for inhibiting expression of the ALAS1 gene | Oct 03, 2034 | Alnylam Pharms Inc |
| Givlaari | US11530408 | Therapeutic compositions |
May 18, 2024
(Expired) | Alnylam Pharms Inc |
| Givlaari | US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 12, 2029 | Alnylam Pharms Inc |
| Givlaari | US8546143 | Compositions and methods for inhibiting expression of a target gene |
Jan 09, 2022
(Expired) | Alnylam Pharms Inc |
| Givlaari | US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides | Dec 04, 2028 | Alnylam Pharms Inc |
| Givlaari | US9133461 | Compositions and methods for inhibiting expression of the ALAS1 gene | Nov 30, 2033 | Alnylam Pharms Inc |
| Givlaari | US9150605 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | Aug 28, 2025 | Alnylam Pharms Inc |
| Givlaari | US9631193 | Compositions and methods for inhibiting expression of the ALAS1 gene | Mar 15, 2033 | Alnylam Pharms Inc |
| Givlaari | US9708610 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan 01, 2024
(Expired) | Alnylam Pharms Inc |
| Givlaari | US9708615 | Therapeutic compositions |
Mar 08, 2024
(Expired) | Alnylam Pharms Inc |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳